Filter by Interests
Filter by ContentType
The future is now: AI-enabled RNA–LNP discovery
Bowen Li
11 April 2025
Interview
Pandemic preparedness and the future of RNA therapeutics: RNA readiness and response
Duccio Medini
03 April 2025
Interview
Addressing regulatory hurdles for individualized mRNA cancer immunotherapies: insights into the MHRA’s new guidance for developers
Francis Galaway
11 February 2025
Interview
Improving lipid nanoparticle formulations for targeted delivery of genome editors
Rohit Sharma
05 November 2024
Interview
Understanding DNA starting material for mRNA production
Lawrence Thompson
30 October 2024
Interview
Advancing mRNA production through platform and continuous process development
Zoltan Kis
25 September 2024
Interview
Advancing delivery of RNA therapeutics with cationizable xenopeptides
Ernst Wagner
24 September 2024
Interview
Delving into the unknowns of mRNA-LNP formulation and characterization
Ramesh Marasini
15 July 2024
Interview
From bench to bedside: advancing mRNA therapies for cardiovascular diseases
Ajit Magadum
27 June 2024
Interview
Harnessing the potential of AI/ML to expand the horizons of the oligonucleotide therapeutics field
Arijit Bhowmick
27 June 2024
Interview
Evolution of mRNA-based vaccines: a regulator’s view
Ka-Wai Wan
22 May 2024
Interview
Moving mRNA–LNP therapeutics towards the clinic: overcoming myths and misconceptions to solve the specificity challenge
Ansgar Santel, Jörg Kaufmann
21 May 2024
Interview
Focusing on the fundamentals: what do and don’t we know about mRNA delivery?
Colin Pouton, Angus Johnston
04 March 2024
Interview
Harnessing the differentiated capabilities of mRNA for rare diseases
Paolo Martini
23 February 2024
Interview
Charting a course for the expanded application of mRNA vaccine technology
Myriam Mendila
23 February 2024
Interview
Delivering on the promise of mRNA cancer vaccines in the immuno-oncology clinical setting
Jane Healy
23 February 2024
Interview
Pioneering nucleic acid breakthroughs for the world
Robert Langer
23 February 2024
Interview
Wall Street analyst’s perspective: taking the pulse of the nucleic acid-based prophylactic & therapeutic vaccine sectors
Hartaj Singh
23 February 2024
Interview
Developing an mRNA–LNP vaccine to combat Lyme disease
Matthew Pine
20 December 2023
Interview
Expanding the potential of in vivo cell therapy with tLNP-RNAs (targeted lipid nanoparticle-RNA)
Adrian Bot
28 June 2023
Interview
Pushing the frontiers of mRNA formulation & delivery
Mohamed EH ElSayed
23 April 2023
Interview